Humanigen, Inc. (HGEN)
Chart Events
Performance Outlook
| Previous Close | 0.0003 |
| Open | 0.0002 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.0002 - 0.0005 |
| 52 Week Range | 0.0001 - 0.2390 |
| Volume | |
| Avg. Volume | 278,643 |
| Market Cap | 59,540 |
| Beta (5Y Monthly) | -0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings Date | Dec 11, 2023 - Dec 22, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.15 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HGEN
Related Research
- Humanigen, Inc.Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.RatingFair ValueEconomic Moat2 days agoMorningstar
NewsfileHumanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host DiseasePlanned interim assessment expected in 2024 following treatment of first 20 participantsShort Hills, New Jersey--(Newsfile Corp. - August 7, 2023) - Humanigen, Inc. (OTC Pink: HGEN), a clinical-stage biopharmaceutical company, today announced successful dosing of
NewsfileHumanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durableCMML
NewsfileHumanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty L
